Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LISATA THERAPEUTICS, INC. (CLBS)
|
Add to portfolio |
|
|
|
| Price: |
$1.03
| | Metrics |
| OS: |
8.14
|
M
| |
|
|
| Market cap: |
$8.39
|
M
| |
|
|
|
Net cash:
|
$57.6
|
M
| |
$7.08
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 22.5 | 17.9 |
| Revenue growth | | | | | | -100.0% | 25.4% | 22.3% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.2 | 15.7 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3 | 2.3 |
| Gross margin | | | | | | | 10.4% | 12.6% |
| Selling, general and administrative | 11.4 | 9.9 | 9.3 | 9.4 | 11.8 | 12.8 | 30.0 | 30.8 |
| Research and development | 17.7 | 9.3 | 10.8 | 7.6 | 15.8 | 16.7 | 23.9 | 29.2 |
| EBITA | -29.1 | -19.1 | -20.1 | -17.0 | -27.6 | -29.5 | -51.0 | -57.1 |
| EBITA margin | | | | | | | -226.7% | -318.5% |
| Amortization of intangibles | | | | | | | 0.6 | 0.6 |
| EBIT | -29.1 | -19.1 | -20.1 | -17.0 | -27.6 | -29.5 | -51.6 | -57.7 |
| EBIT margin | | | | | | | -229.4% | -321.9% |
| Pre-tax income | -29.0 | -19.0 | -19.4 | -16.2 | -27.7 | -31.3 | -98.3 | -55.6 |
| Income taxes | -1.5 | -10.9 | 0.0 | 0.0 | -11.5 | 0.0 | -17.2 | -0.1 |
| Tax rate | 5.2% | 57.2% | 0.0% | 0.0% | 41.6% | 0.0% | 17.5% | 0.2% |
| Earnings from continuing ops | -27.5 | -8.1 | -19.4 | -16.2 | -16.2 | -31.3 | -80.9 | -54.9 |
| Earnings from discontinued ops | | | | | 38.4 | -2.1 | | |
| Net income | -27.5 | -8.1 | -19.4 | -16.2 | 22.2 | -33.3 | -80.9 | -54.9 |
| Net margin | | | | | | | -359.7% | -305.9% |
| |
| Diluted EPS | ($0.50) | ($0.53) | ($1.87) | ($1.67) | ($1.80) | ($4.77) | ($16.67) | ($1.68) |
| Shares outstanding (diluted) | 55.3 | 15.4 | 10.3 | 9.7 | 9.0 | 6.5 | 4.9 | 32.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|